Entrada selects clinical candidate ENTR-601-45 for DMD exon 45 skipping; IND in H2 2024

Entrada Therapeutics, Inc.

ENTR-601-45 is an EEV-conjugated PMO targeting Duchenne patients amenable to exon 45 skipping.
In vivo data showed >90% exon skipping in skeletal muscle of hDMD mouse model after single IV dose.
More than 1,300 patients in US and Europe are exon 45 skipping amenable, per Entrada.
Company plans to submit IND application in second half of 2024.
Additional data expected at MDA Clinical & Scientific Conference in March 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.